Analysis and stability of polymorphs in tablets: The case of Risperidone

Talanta

Volumn 71, Issue 3, 2007, Pages 1382-1386

  Karabas, I ^a,b   Orkoula, M G ^a,b   Kontoyannis, C G ^a,b  

^a UNIVERSITY OF PATRAS   (Greece)

^b INSTITUTE OF CHEMICAL ENGINEERING SCIENCES   (Greece)

Author keywords

FT IR; Polymorphs; Raman; Risperidone; Tablets; X ray powder diffraction

Indexed keywords

FOURIER TRANSFORM INFRARED SPECTROSCOPY; INFRARED SPECTROSCOPY; PHASE COMPOSITION; RAMAN SPECTROSCOPY; STABILITY; X RAY POWDER DIFFRACTION;

CRYSTAL PHASES; POLYMORPHS; RISPERIDONE; TABLETS;

DRUG PRODUCTS;

EID: 33846539683     PISSN: 00399140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.talanta.2006.07.009     Document Type: Article

References (6)

1. Grant D.J. In: Brittain H.G. (Ed). Polymorphism in Pharmaceutical Solids (1999), Marcel Dekker, Inc., New York 1-31 (Chapter 1)
2. International Conference on Harmonization Q6A Guideline: Specifications for New Drug Substances and Products: Chemical Substances, October 1999.
3. Brittain H.G., and Fiese E.F. In: Brittain H.G. (Ed). Polymorphism in Pharmaceutical Solids (1999), Marcel Dekker, Inc., New York 279-330 (Chapter 8)
4. Brittain H.G. In: Brittain H.G. (Ed). Polymorphism in Pharmaceutical Solids (1999), Marcel Dekker, Inc., New York 227-271 (Chapter 6)
5. Morissette S., Almarsson O., Peterson M., Remenar J., Read M., Lemmo A., Ellis S., Cima M., and Gardner C. Adv. Drug Deliv. Rev. 56 (2004) 275
6. B. Krochmal, D. Diller, B.-Z. Dolitzky, J. Aronhime, Preparation of Risperidone, U.S. Patent No. 6,750,341 and PCT/WO 02/12200 A1, Feb 14, 2002.